These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7822865)

  • 1. Human antibodies to recombinant factor VII in hemophiliacs.
    Lusher JM
    J Interferon Res; 1994 Aug; 14(4):173-4. PubMed ID: 7822865
    [No Abstract]   [Full Text] [Related]  

  • 2. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
    Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
    Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials of the recombinant factor VIII product, Kogenate.
    Inwood M; Lusher J
    Transfus Med Rev; 1992 Oct; 6(4):261-2. PubMed ID: 1421826
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 6. HLA antigens in hemophiliacs A with or without factor VIII antibodies in a Venezuelan Mestizo population.
    Simonney N; De Bosch N; Argueyo A; Garcia E; Layrisse Z
    Tissue Antigens; 1985 Apr; 25(4):216-9. PubMed ID: 3925592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 10. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion.
    Burnouf T; Strengers PF
    J Thromb Haemost; 2016 Oct; 14(10):2073-2074. PubMed ID: 27496669
    [No Abstract]   [Full Text] [Related]  

  • 12. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B; Evensen SA; Stavem P
    Tidsskr Nor Laegeforen; 1977 Apr; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract]   [Full Text] [Related]  

  • 13. Making clinical decisions on the basis of RODIN.
    Mannucci PM
    Haemophilia; 2014 Mar; 20(2):e174-5. PubMed ID: 24533956
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevalence of inhibitors in hemophiliacs with reference to the transfusion of blood products (author's transl)].
    Kamiya T
    Rinsho Byori; 1978; 26(4):291-7. PubMed ID: 671775
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates.
    Vincent AM; Lillicrap D; Boulanger A; Meilleur C; Amesse C; St-Louis J; Rivard GE
    Haemophilia; 2009 Jan; 15(1):374-6. PubMed ID: 19149862
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anti-HTLV-III antibodies in hemophiliacs treated with concentrates of factors VIII or IX].
    Aznar JA; Granda D; Jorquera J; González-Molina A; Carmona E; Peiró A; Gobernado M
    Sangre (Barc); 1985; 30(5):934-5. PubMed ID: 3937254
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 20. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST; Addiego JE; Reason DC; Lucas AH
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.